Hormone Screening for Adrenal Incidentalomas: ESE Guideline Requirements
Yes, according to the most recent guidelines, all patients with adrenal incidentalomas must be screened for hormone excess at least once, with the sole exception being patients with limited life expectancy or critical illness.
Universal Screening Mandate
The evidence is unequivocal: all patients with adrenal incidentalomas should be screened for autonomous cortisol secretion 1. This represents a fundamental principle in adrenal incidentaloma management, as biochemical screening remains mandatory in most patients 2.
Algorithmic Approach to Hormone Screening
1. Cortisol Screening (Universal - All Patients)
- Test: 1 mg dexamethasone suppression test (DST) - taken at 11 PM, serum cortisol measured at 8 AM 1
- Interpretation:
- ≤50 nmol/L (≤1.8 μg/dL): Excludes cortisol hypersecretion
- 51-138 nmol/L: Possible autonomous cortisol secretion (mild autonomous cortisol secretion/MACS)
138 nmol/L: Evidence of cortisol hypersecretion
- Rationale: MACS affects 20-50% of patients and is associated with cardiovascular event rates of 15.5% over 50-60 months 2
2. Aldosterone Screening (Conditional)
- Who: Only patients with hypertension and/or hypokalemia 1
- Test: Aldosterone-to-renin ratio (ARR)
- Threshold: ARR >20 ng/dL per ng/mL/hr has >90% sensitivity and specificity 1
- Timing: Morning, after 2 hours upright, seated 5-15 minutes, potassium-replete
3. Pheochromocytoma Screening (Risk-Stratified)
- Screen if:
- Do NOT screen if: Unequivocal adrenocortical adenoma with ≤10 HU and no adrenergic symptoms 1, 2
- Test: Plasma free metanephrines or 24-hour urinary metanephrines
- Threshold: >2× upper limit of normal 1
4. Androgen Screening (Highly Selective)
- Who: Only patients with suspected adrenocortical carcinoma or clinical virilization 1
- Tests: DHEAS, testosterone
Critical Clinical Nuances
The "Benign Adenoma Exception"
A homogeneous adrenal mass with ≤10 HU on non-contrast CT requires no further follow-up imaging, irrespective of size 3, 4. However, this does NOT exempt the patient from initial hormone screening—only from repeat imaging. Emerging evidence suggests expanding this threshold to ≤20 HU may maintain 99.4-99.8% positive predictive value 2, though this remains investigational.
Common Pitfalls to Avoid
Don't assume the visible lesion is functional: A patient may have an adrenal incidentaloma but harbor Cushing disease from a pituitary adenoma or primary aldosteronism from the contralateral adrenal gland 5. Localization studies are essential before attributing hormone excess to the visible mass.
Don't skip cortisol screening in "benign-appearing" lesions: Even lipid-rich adenomas (≤10 HU) can be hormonally active. The 2023 guidelines mandate cortisol screening for all patients regardless of imaging characteristics 1.
Don't order washout CT reflexively: Historical reliance on washout CT is increasingly questioned due to cost-effectiveness concerns and inability to exclude pheochromocytoma 2. Use it only for indeterminate masses after non-contrast CT.
Strength of Evidence
The recommendation for universal cortisol screening carries strong consensus across multiple 2023 guidelines [1-1], representing the highest quality guideline evidence available. The CUA/AUA 2023 guideline explicitly states this as Recommendation 6.1 with moderate quality evidence 1. The function-driven paradigm is further validated by real-world data showing hormonal activity strongly predicts clinically significant pathology (81.7% vs 4.3%, p<0.001), whereas tumor size alone does not 6.
The Single Exception
The only patients who may forgo hormone screening are those with limited life expectancy or critical illness 2. This is a clinical judgment call based on whether the results would meaningfully alter management or improve quality of life.